ViAqua Therapeutics
ViAqua Therapeutics
Agent49Agent Readiness: 49/100. Top 25%. Measured by StartupHub.ai. Median 41.Develops novel oral RNA delivery platforms for aquaculture health management, focusing on disease resistance.
About
ViAqua Therapeutics addresses the critical need for effective and affordable health management solutions in the aquaculture industry. Their primary innovation is a novel oral delivery platform designed to deliver RNA, aiming to induce resistance to diseases like White Spot Shrimp Virus. This technology was co-developed with Skretting, a Nutreco company.
Key facts
At-a-glance profile data
- Website
- viaqua-t.com
- Headquarters
- Rehovot, Israel
- Founded
- 2014
- Employees
- 14
- Total funding
- $13M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 5 Sept 2023 | Series A | $8M | S2G Ventures |
| 9 Jun 2021 | Seed | $4M | S2G Ventures, Thai Union, Agriline |
Tech stack
Detected on viaqua-t.com, last scanned 23 Sept 2026. Run your own scan
- Observability
- Sentry
- CMS / Builders
- Wix
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has ViAqua Therapeutics raised?
ViAqua Therapeutics has raised a total of $13M in funding. The most recent round on record is Series A.
How many employees does ViAqua Therapeutics have?
ViAqua Therapeutics has approximately 14 people on record.